Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ORLANDO PORTAL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1366626111
CMS profile
1170705
Location
RIVERVIEW, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$339.77

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $324.87 19
Education $14.90 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ORLANDO PORTAL

NPI 1366626111 · CMS profile ID 1170705

Allopathic & Osteopathic Physicians / Internal Medicine

RIVERVIEW, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366626111?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ORLANDO PORTAL, NPI 1366626111, CMS profile ID 1170705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366626111?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ORLANDO PORTAL, NPI 1366626111, CMS profile ID 1170705. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366626111?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ORLANDO PORTAL, NPI 1366626111, CMS profile ID 1170705, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1366626111?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $339.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $21.0912/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685922187 CMS
PFIZER INC. $12.5811/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673676335 CMS
AstraZeneca Pharmaceuticals LP $21.0911/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685509745 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.9011/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700218999 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7610/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684887979 CMS
Novartis Pharmaceuticals Corporation $18.7710/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659895185 CMS
Lilly USA, LLC $11.7110/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658068091 CMS
Novo Nordisk Inc $15.2310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674992329 CMS
Novo Nordisk Inc $24.6809/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674573421 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.1009/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700218997 CMS
Allergan Inc. $11.1609/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670961435 CMS
Novo Nordisk Inc $24.4508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674611645 CMS
Janssen Pharmaceuticals, Inc $12.5907/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659206015 CMS
Janssen Pharmaceuticals, Inc $12.5907/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659206013 CMS
Novo Nordisk Inc $21.9106/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674465281 CMS
Janssen Pharmaceuticals, Inc $21.1605/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659206011 CMS
Janssen Pharmaceuticals, Inc $18.7703/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659206009 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.4603/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684887973 CMS
AstraZeneca Pharmaceuticals LP $19.7502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685762911 CMS
Janssen Pharmaceuticals, Inc $12.0202/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659206007 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $339.77 20
PY2020 $298.44 13
PY2021 $266.84 14
PY2022 $319.46 11
PY2023 $326.18 20
PY2024 $297.63 17
PY2025 $444.62 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $36,684.90 12
PY2024 Principal investigator $133,245.43 14
PY2023 Recipient $234,416.46 5
PY2023 Principal investigator $136,269.05 9
PY2022 Principal investigator $466,568.40 55
PY2021 Principal investigator $384,286.25 64
PY2020 Principal investigator $42,422.64 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 12/16/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838454417
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 12/16/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838454425
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 11/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838446803
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 11/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838446811
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439841
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439849
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439857
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439865
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439873
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439881
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439889
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439897
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 10/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838439905
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,250.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027883
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $750.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027885
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027887
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $500.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027889
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $750.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027891
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,000.00 09/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851027893
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,300.00 08/19/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026899
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428359
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428369
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428373
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428384
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428391
Principal investigator 1 Esperion Therapeutics, Inc. $385.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428399
Principal investigator 1 Esperion Therapeutics, Inc. $385.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428405
Principal investigator 1 Esperion Therapeutics, Inc. $385.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428413
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428421
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 07/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838428429
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,000.00 07/26/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026361
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $25,801.20 07/26/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026363
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,295.00 07/12/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026119
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $5,250.00 07/12/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851026121
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $142,469.25 07/08/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851026009
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $45,486.90 06/29/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851025443
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 06/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420833
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 06/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838420841
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $4,500.00 06/17/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025123
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 06/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413777
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 06/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413785
Principal investigator 1 Esperion Therapeutics, Inc. $48.00 06/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838413793
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $6,250.00 05/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024695
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $61,857.90 05/27/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024697
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $29,700.00 05/19/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 851024459
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 04/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838405461
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 04/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838405469
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 04/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838405475
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 04/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838405481
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 04/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838405489
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 03/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401425
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 03/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838401433
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 02/22/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838395085
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $20,375.00 02/11/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021617
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,145.64 02/11/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021869
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391745
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391753
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391761
Principal investigator 1 Esperion Therapeutics, Inc. $657.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391857
Principal investigator 1 Esperion Therapeutics, Inc. $385.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391865
Principal investigator 1 Esperion Therapeutics, Inc. $385.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391871
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391879
Principal investigator 1 Esperion Therapeutics, Inc. $230.00 02/01/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 838391885
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $8,388.36 01/14/2021 Non-covered Recipient Entity
JSV CLINICAL RESEARCH STUDY INC
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851020073